Biomarkers.

Background: Two main risk factors of Alzheimer's disease (AD) are aging and APOE-ε4. However, some individuals remain cognitively normal despite having these risk factors. They are considered "cognitively resilient".

Biomarkers.

Background: Alzheimer's disease (AD) is the most prevalent neurodegenerative disease, yet our comprehension predominantly relies on studies within the non-Hispanic White (NHW) population. To address this, Accelerating Medicines Partnership in AD (AMP-AD) aimed to promote inclusivity in multi-omics AD research, to unravel unique molecular signatures and pathways. The study aimed to provide comprehensive insights into the proteomic landscape of AD across diverse racial groups.

Biomarkers.

Background: Alzheimer's disease (AD) patients have decline in cognitive domains including memory, language, visuospatial, and/or executive function and brain pathology including amyloid-β and tau deposition, neurodegeneration, and frequent vascular co-pathologies detectable by neuroimaging and/or cerebrospinal fluid biomarkers. However, molecular disease mechanisms are complex and heterogeneous. It is necessary to develop cost-effective blood-based biomarkers reflecting brain molecular perturbations in AD.

Biomarkers.

Background: Plasma biomarker development is of increasing interest due to improved accessibility compared to established diagnostic modalities for Alzheimer's disease (AD). However, current plasma biomarker candidates have not been tested comprehensively in diverse populations, and these markers represent only a fraction of pathways perturbed in AD. Therefore, there is a need to identify novel plasma biomarkers that account for both disease heterogeneity and patient diversity.